Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The Danish maker of Ozempic and Wegovy reported a 25 percent ... disappointing trial results of its next-generation weight loss drug CagriSema. After a late-stage trial slightly missed expectation ...

Novo Nordisk sells the drug semaglutide under the brands Ozempic for diabetes and Wegovy for weight loss. The company's older weight loss drug, liraglutide, is marketed as Victoza for diabetes and ...

Amy Schumer has revealed she quickly turned away from using Ozempic to lose weight after suffering vomit fuelled side-effects. The comedian and actress, 43, has admitted using the drug - which is ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...

With weight loss drugs such as Ozempic and Mounjaro seemingly able to melt the pounds away, you might well think you'll never need a 'diet plan' again. Alas, you'd be wrong. As a leading weight ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.